Mameli, Giuseppe and Cossu, Davide and Caggiu, Elisa and Arru, Giannina and Niegowska, Magdalena and Cocco, Eleonora and Frau, Jessica and Marrosu, Maria Giovanna and Sechi, Leonardo Antonio (2016) Soluble BAFF level is not correlated to Mycobacterium avium subspecies paratuberculosis antibodies and increases after interferon-β therapy in multiple sclerosis patients. Journal of Molecular Neuroscience, Vol. 60 (1), p. 91-93. ISSN 0895-8696. eISSN 1559-1166. Article.
Full text not available from this repository.
B cells are being recognized as one of the major players in the pathogenesis of multiple sclerosis (MS). The B cell activating factor (BAFF) system plays an essential role in B cell homeostasis and function in the periphery. Mycobacterium avium subspecies paratuberculosis (MAP) has been previously associated to MS in Sardinia. Antibodies against a MAP surface protein, MAP_2694, have been found significantly associated to MS patients, and this response was modified by interferon-β therapy. Increased BAFF levels following IFN-β therapy have been also described in MS patients. In this study, we evaluated whether soluble BAFF levels are comparable in men and women affected by MS and performed a correlation of the reported BAFF increase in MS patients under IFN-β therapy with changes of humoral response against MAP_2694. For these reasons, we investigated 44 MS patients before and after IFN-β therapy. A significant difference of BAFF levels was found between men and women with MS; moreover, we confirmed that IFN-β therapy strongly induces BAFF serum levels, but this was not related to the modification of immunological response against MAP_2694. In conclusion, our study highlights that IFN-β therapy induces the potent B cell survival factor BAFF without alterations of the humoral immune response against MAP.
I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore
Repository Staff Only: item control page